31
Participants
Start Date
August 31, 2014
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
PF-06664178
Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
PF-06664178
Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
Anschutz Cancer Pavilion, Aurora
University of Colorado Denver CTO (CTRC), Aurora
University of Colorado Hospital, Aurora
Keck Hospital of USC, Los Angeles
LAC&USC Medical Center, Los Angeles
USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles
USC/Norris Comprehensive Cancer Center, Los Angeles
Swedish Medical Center, Seattle
Seattle Cancer Care Alliance, Seattle
University of Washington Medical Center, Seattle
Lead Sponsor
Pfizer
INDUSTRY